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Abstract
Background: An i ncreasing number of  re ports i s challenging the notion that the antitumor
potential of the selective COX-2 inhibitor celecoxib (Celebrex®) is mediated primarily via the
inhibition of COX-2. We have investigated this issue by applying two different analogs of celecoxib
that differentially display COX-2-inhibitory activity: the first analog, called unmethylated celecoxib
(UMC), inhibits COX-2 slightly more potently than its parental compound, whereas the second
analog, 2,5-dimethyl-celecoxib (DMC), has lost the ability to inhibit COX-2.
Results: With the use of glioblastoma and pancreatic carcinoma cell lines, we comparatively
analyzed the effects of celecoxib, UMC, and DMC in various short-term (≤48 hours) cellular and
molecular studies, as well as in long-term (≤3 months) focus formation assays. We found that DMC
exhibited the most potent antitumor activity; celecoxib was somewhat less effective, and UMC
clearly displayed the overall weakest antitumor potential in all aspects. The differential growth-
inhibitory and apoptosis-stimulatory potency of these compounds in short-term assays did not at
all correlate with their capacity to inhibit COX-2, but was closely aligned with their ability to trigger
endoplasmic reticulum stress (ERS), as indicated by the induction of the ERS marker CHOP/
GADD153 and activation of the ERS-associated caspase 7. In addition, we found that these
compounds were able to restore contact inhibition and block focus formation during long-term,
chronic drug exposure of tumor cells, and this was achieved at sub-toxic concentrations in the
absence of ERS or inhibition of COX-2.
Conclusion: The antitumor activity of celecoxib in vitro did not involve the inhibition of COX-2.
Rather, the drug's ability to trigger ERS, a known effector of cell death, might provide an alternative
explanation for its acute cytotoxicity. In addition, the newly discovered ability of this drug to
restore contact inhibition and block focus formation during chronic drug exposure, which involved
neither ERS nor COX-2, suggests a novel, as yet unrecognized mechanism of celecoxib action.
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Introduction
Celecoxib (CXB) has been developed as a selective inhib-
itor of cyclooxygenase-2 (COX-2) and is widely prescribed
under the trade name Celebrex® for relief of symptoms of
osteoarthritis and rheumatoid arthritis; it was also
approved as an adjunct to the standard of care for patients
with familial adenomatous polyposis (FAP) [1]. In the
laboratory, CXB has demonstrated anti-cancer activity in
various animal tumor models, and it is suspected that this
drug might be useful for the prevention and treatment of
colorectal and possibly other types of cancer as well [2-4].
Indeed, several clinical trials have demonstrated CXB's
potency to reduce colorectal polyp and adenoma forma-
tion in humans [1,5,6]. However, these promising results
were overshadowed by concomitantly emerging side
effects, such as life-threatening cardiovascular complica-
tions, which are thought to be caused by the long-term
inhibition of COX-2 (reviewed in [7]).
The underlying molecular mechanisms by which CXB
exerts its anti-tumor effects have become controversial,
primarily due to an increasing number of reports describ-
ing effects of this drug that appear to take place in the
absence of any apparent involvement of COX-2 (see refs.
[8-10] for review). In this regard, several non-COX-2 com-
ponents of the cell have been identified and proposed as
candidates for mediating the COX-2-independent antitu-
mor effects of CXB. One of the best studied and perhaps
most relevant of these alternative targets is sarcoplasmic/
endoplasmic reticulum (ER) calcium ATPase (SERCA)
[11-13], which is an ER transmembrane protein that is
responsible for pumping calcium from the cytosol into
the ER, thereby maintaining the steep gradient of this ion
between the two subcellular compartments.
Inhibition of SERCA represents the earliest detectable
effect of drug action, as increased cytosolic calcium levels
can be measured within seconds of adding CXB to cul-
tured cells [11-15]. Leakage of calcium from the ER has
long been known to act as a potent trigger of ER stress, and
ER stress-instigated cell death can indeed be verified after
CXB treatment of tumor cells in vitro and in animal tumor
models in vivo [12,16-19]. Known critical executioners of
the pro-apoptotic arm of the ER stress response are, for
example, CHOP/GADD153 (CCAAT/enhancer binding
protein homologous transcription factor/growth arrest
and DNA damage-inducible gene 153) and caspase 7,
both of which are strongly stimulated by CXB treatment
(for example, refs. [16,17,19-21]. Altogether, the discov-
ery of SERCA and subsequent ER stress as a direct target of
CXB, in combination with a host of other observations
[8], has seriously challenged the notion that inhibition of
COX-2 might be the critical event mediating the antitu-
mor outcomes of CXB treatment [10,22].
In an effort to shed further light on this controversy, we
have investigated the in vitro antitumor potential of two
close structural analogs of CXB with either increased or
greatly decreased COX-2-inhibitory activity. The first ana-
log, unmethylated-celecoxib (UMC), harbors 20% greater
COX-2-inhibitory potency than CXB. The second analog,
2,5-dimethyl-celecoxib (DMC), lacks COX-2-inhibitory
potency. In this report, we show that the antitumor
potency of these compounds is DMC>CXB>UMC, i.e., the
antitumor effects of these drugs are in inverse relation to
their COX-2-inhibitory potential, but are closely aligned
with their ability to trigger ER stress.
Results
CXB and UMC, but not DMC, inhibit COX-2 and block 
PGE2 biosynthesis
Figure 1 summarizes the chemical structures and proper-
ties of celecoxib (CXB) and its two analogs that were used
in our study. CXB has one methyl group at the C-4 (p)
position of its terminal phenyl ring; the methyl substitu-
tion is lacking in unmethylated-celecoxib (UMC); in con-
trast, 2,5-dimethyl-celecoxib (DMC) has two methyl
groups (at the 2- and 5-positions) of the phenyl ring. The
COX-2 inhibitory potency of these compounds was first
described by Penning et al. [23], and is shown in Figure 1.
Note that UMC is the most potent COX-2 inhibitor, fol-
lowed by CXB, and DMC essentially is lacking any sub-
stantial COX-2-inhibitory potency.
Because the COX-2-inhibitory activity of the three com-
pounds had been determined by in vitro assays with puri-
fied recombinant COX-2 enzyme [23], we next verified
that these compounds exerted their activities also when
added to cells in culture. For this purpose, we used a
human pancreatic carcinoma cell line with high COX-2
expression levels and determined whether increasing con-
centrations of CXB, UMC, or DMC were able to block the
synthesis of the COX-2 substrate prostaglandin E2
(PGE2). As shown in Figure 1, both CXB and UMC effec-
tively prevented the formation of PGE2 with an IC50
below 1 µM and 100% inhibition at 10 µM. In contrast,
DMC did not display substantial inhibitory activity; even
at 10 µM, there was only a minor reduction (22%) of
PGE2 biosynthesis. Together, these measurements con-
firmed that CXB and UMC were able to potently inhibit
COX-2 in cell culture, and that DMC was much (at least
100-fold) less active.
CXB, UMC, and DMC trigger ER stress and reduce cell 
viability at different potencies
To determine how CXB, UMC, and DMC would affect cell
proliferation and survival, we treated three different gliob-
lastoma cell lines (LN229, U251, and T98G) with increas-
ing concentrations of these compounds and determined
cell viability by MTT assay. As shown in Figure 2, DMCMolecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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Chemical structures and activities of CXB, UMC, and DMC Figure 1
Chemical structures and activities of CXB, UMC, and DMC. CXB has one methyl group at the C-4 (p) position of its 
terminal phenyl ring; this substitution is lacking in UMC; DMC has two methyl groups (at the 2- and 5-positions). The listed 
COX-2 inhibitory potency (IC50) of these compounds is derived from two earlier studies that used human recombinant COX-
2 in vitro [23, 42]. The bottom chart displays PGE2 levels (mean ± SE, n = 4) in the culture medium of Bx-PC-3 cells pretreated 
for 30 minutes with the indicated drug concentrations and then stimulated with 10 µM arachidonic acid, as previously 
described by Eibl et al. [25].
potently reduced cell viability with an IC50 in the range of
35–45 µM; CXB was slightly less potent with an IC50 of
55–65  µM. In comparison, UMC showed the weakest
cytotoxic effects and its IC50 was >100 µM. When addi-
tional human tumor cell lines were tested, such as multi-
ple myeloma, breast carcinoma, or lymphoma (all of
which displayed greatly varying levels of COX-2 expres-
sion), very similar outcomes were observed (not shown).
In all cases, DMC was the most cytotoxic compound, CXB
was 20–30% weaker, and UMC was the weakest, exposing
an obvious lack of correlation between the COX-2-inhib-
itory efficacy of these compounds and their cytotoxic
potential. In addition, the exogenous addition of PGE2
was unable to overcome the growth-inhibitory effect of
these drugs (not shown; see [24] for celecoxib), further
indicating that alterations in PGE2 levels had no major
consequence for cell proliferation in these cells.
Because it was reported before that ER stress might be a
critical mechanism by which celecoxib exerts its antitu-
mor function, we investigated two established markers of
ER stress, i.e., the pro-apoptotic protein CHOP and cas-
pase 7. U251 glioblastoma cells were treated with differ-
ent concentrations of CXB, UMC, and DMC, and cell
lysates were analyzed by Western blot. As shown in Figure
3, all three drugs were able to stimulate CHOP expressionMolecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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Reduced cell growth and survival in the presence of CXB, UMC, and DMC Figure 2
Reduced cell growth and survival in the presence of CXB, UMC, and DMC. Three different glioblastoma cell lines 
(LN229, U251, T98G) were treated with the indicated concentrations of CXB, UMC, or DMC. After 48 hours, MTT assays 
were performed to indicate the overall viability in response drug treatment. The right panels show representative 96-well 
plates of treated cells. Deep purple indicates fully viable cell cultures, whereas yellow color reveals drug cytotoxicity (each con-
dition was tested in duplicate). The charts on the left present the quantitative readout of the optical density of the 96-well 
plates (average of two wells each). The whole experiment was independently repeated and yielded very similar outcomes.Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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levels and trigger activation of caspase 7. However, the
respective effective concentrations differed substantially.
In the case of CHOP induction, 40 µM DMC was as effec-
tive as 60 µM CXB, but UMC even at 100 µM displayed
overall weaker effects. In the case of caspase 7 activation,
60 µM DMC was approximately as potent as 75 µM CXB,
but UMC, again, even at 100 µM displayed weaker effects.
In addition, we examined the cleavage of PARP (poly-
ADP-ribose polymerase), which serves as an indicator of
ongoing apoptosis. As before, DMC displayed the strong-
est effects on PARP cleavage; CXB was somewhat less
potent and UMC exhibited only weak effects. Thus, over-
all, the effects of the three drugs on molecular markers of
ER stress and apoptosis correlated with their cytotoxic
potency (as shown in Figure 2), but not with their ability
to inhibit COX-2.
CXB, UMC, and DMC block focus formation at different 
potencies
Because the above assays were focused on rather short-
term (up to 48 hours) drug effects, we decided to include
additional experiments that allowed the evaluation of
phenotypic responses during much longer periods of drug
exposure (up to 3 months). In this regard, we chose focus
formation assays, as these would enable the characteriza-
tion of drug effects on a select tumor-specific feature and
would exclude short-term cytotoxic effects that might
mask other, more long-term consequences of drug treat-
ment. The focus formation assays were performed at lower
drug concentrations that were not readily toxic, but
allowed the cells to form a confluent monolayer, which is
a prerequisite for focus formation.
U251 glioblastoma cells were seeded at low density and
were cultured in the continuous presence of increasing
concentrations of CXB, UMC, or DMC for up to 3 months.
Because the cell cultures were not split during this period,
Increased expression of markers for ER stress and apoptosis in response to treatment with CXB, UMC, and DMC Figure 3
Increased expression of markers for ER stress and apoptosis in response to treatment with CXB, UMC, and 
DMC. U251 glioblastoma cells were treated with the indicated concentrations of CXB, UMC, and DMC and cell lysates were 
analyzed by Western blot with specific antibodies to CHOP (a pro-apoptotic ER stress indicator protein), cleaved (i.e., acti-
vated) caspase 7 (an ER stress-associated protein that participates in the execution of apoptosis), and PARP (proteolytic cleav-
age of PARP is executed by caspase 3 and indicates ongoing apoptosis). To verify equal loading in each case, the blots were also 
probed with an antibody to actin. The top panels represent lysates from cells treated with drugs for 18 hours (to reveal earlier 
events during ER stress). The bottom panels represent lysates from cells treated with drugs for 48 hours (to reveal later stages 
of ER stress-induced apoptosis). f.l.: full length PARP; cl.: cleaved PARP.Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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they formed dense monolayer cultures over time. In the
absence of drug treatment, the cells began to aggregate
and form foci after approximately 12 days; over the course
of the following weeks, these foci developed into large,
very tight spheres of compacted cells that were raised
above the residual monolayer (Figure 4A). In contrast, in
the presence of 30 µM CXB, focus formation was com-
pletely prevented (Figure 4A). Similarly, DMC and UMC
were able to prevent focus formation, but differential drug
concentrations were required. As shown in Figure 4B, the
lowest effective concentrations were 20 µM for DMC, 30
µM for CXB, and 50 µM for UMC. It is noteworthy that
these drug concentrations did not block tumor cell prolif-
eration and did not prevent the formation of a complete
monolayer, although the overall rate of cell proliferation
was very slightly reduced, i.e., it took slightly longer for
drug-treated cells to cover the entire surface of the culture
dish. Nonetheless, even during extended culture in the
presence of drugs (up to 3 months), no foci developed at
the above mentioned drug concentrations, whereas in the
absence of drug treatment, there were hundreds of foci per
square inch. Thus, in summary, these results demonstrate
that CXB, UMC, and DMC are able to suppress an impor-
tant indicator of the transformed phenotype, focus forma-
tion, but this effect did not correlate with these drugs'
potency to inhibit COX-2.
CXB, UMC, and DMC display their differential antitumor 
activities in cells with or without COX-2 expression
To further investigate the above mechanisms, we applied
CXB, UMC, and DMC side-by-side to a pair of pancreatic
carcinoma cell lines that had been well characterized pre-
viously with regards to their COX-2 status: MIA-PaCa-2
cells are negative for COX-2 expression, whereas Bx-PC-3
cells express high levels of COX-2 [25,26]. Both cell lines
were exposed to increasing concentrations of the drugs,
and MTT assays were performed 48 hours later. As shown
in Figure 5, both cell lines responded similarly to CXB,
UMC, and DMC. As before in the case of glioblastoma cell
lines (Figure 2), DMC turned out to be the most potent
cytotoxic compound (IC50 ~45 µM), CXB was noticeably
weaker (IC50 60–65 µM), and UMC was the least effective
(IC50>100 µM). Thus, the status of COX-2 expression did
not have an apparent influence on cellular sensitivity to
these drugs.
We next investigated the expression levels of the ER stress
marker CHOP in response to drug treatment of MIA-
PaCa-2 and Bx-PC-3 cells. Here as well, no major differ-
ences could be found between these COX-2-positive and
COX-2-negative cells. As shown in Figure 6, 60 µM DMC
and 75 µM CXB similarly increased CHOP protein levels,
whereas 75 µM UMC had no major effect. This finding
further indicated that induction of ER stress by celecoxib
was independent of any involvement of COX-2.
We also intended to perform focus formation assays with
the MIA-PaCa-2 and Bx-PC-3 pair of cell lines. However,
it turned out that these cells were unable to form the type
of foci typical of many transformed cells. Instead, after
forming a densely packed monolayer, these cells kept pro-
liferating and shed the newly generated cells floating into
the medium. However, in the continuous presence of
CXB, DMC, or UMC, two phenotypic changes became
apparent in both cell lines. First, after the completion of
the monolayer, cell proliferation was greatly reduced and
substantially fewer cells were shed into the medium, i.e.,
contact inhibition appeared to have been restored by drug
treatment. Second, the confluent monolayer was consti-
tuted of larger cells, i.e., there were noticeably fewer cells
per surface area and the cells appeared much less crowded
in the presence of drugs (Figure 7). These phenotypic fea-
tures were quite stable: even after extended periods of
drug exposure (up to 2 months), drug-treated cell cultures
did not display the compactness and density of untreated
control cells. However, substantial differences in drug
potency were noted. As before, DMC was the most potent
compound, CXB was 20–30% less effective, and UMC
clearly was the least effective of these drugs. Taken
together, these results demonstrate that the presence or
absence of COX-2 had no bearing on the phenotypic
responses of these cells to drug treatment, indicating that
CXB achieved these outcomes independently of any COX-
2 involvement.
All of the above-described phenotypic changes were stable
as long as drug treatment was continued, but were fully
reversible after the removal of drugs (not shown). For
instance, when drug treatment of MIA-PaCa-2 and Bx-PC-
3 cells was discontinued after 2 months, the cell cultures
became more crowded, i.e., the cell number per square
inch increased and the monolayer resumed shedding of
new cells into the culture medium; similarly, when drug-
treated U251 monolayers, which had remained focus-free
during 3 months of drug treatment, were trypsinized and
freshly seeded into new culture dishes, they promptly
developed foci in the absence of drug treatment (not
shown). Thus, suppression of the transformed phenotype
in these tumor cells was dependent on the continuous
presence of sub-toxic concentrations of CXB, UMC, or
DMC.
Discussion
The question as to whether the antitumor effects of CXB
are based on its famed ability to inhibit COX-2 has incited
substantial controversy. This issue is particularly relevant
in view of the life-threatening complications that have
emerged during the long-term treatment with elevated
dosages of this drug for chemopreventive or cancer thera-
peutic applications. These unwanted side effects, such as
cardiovascular events, are thought to be due to the long-Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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Prevention of focus formation by CXB, DMC, and UMC Figure 4
Prevention of focus formation by CXB, DMC, and UMC. U251 glioblastoma cells were continuously exposed to vari-
ous concentrations of CXB, DMC, or UMC for up to 3 months in the same cell culture dishes (i.e., without splitting the cell 
monolayers). In A., cells were treated with or without 30 µM CXB and photomicrographs (160× magnification) were taken 
after 12 days and 6 weeks. Top left shows early-stage focus formation (3 representative foci are shown); top right shows 3 
examples of fully developed, very compact foci (each one consisting of an estimated several hundred cells). Neither early-nor 
late-stage foci were present in CXB-treated cell cultures. In B., cells were treated with increasing concentrations of the three 
drugs and photomicrographs (20× magnification) were taken after 10 weeks. Note that in the absence of drug treatment, many 
foci (several hundred per square inch) had developed. However, no foci developed in the presence of 20 or 30 µM DMC, 30 
or 40 µM CXB, and 50 µM UMC (representative sections of each culture are shown).Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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term inhibition of COX-2 and have also been observed
with other coxibs, such as rofecoxib (Vioxx) [7]. In this
regard, one might be tempted to speculate that analogs of
CXB that are devoid of COX-2-inhibitory ability, yet
maintain antitumor potency, might potentially be supe-
rior for certain cancer therapeutic purposes [27].
In order to further investigate the relevance of COX-2 for
CXB's antitumor efficacy, we applied two close structural
analogs of this drug that differentially display COX-2-
inhibitory activity. UMC has maintained COX-2-inhibi-
tory function and is even 20% more potent than its paren-
tal compound; in contrast, DMC is devoid of any
substantial COX-2-inhibitory function. These analogs
originally were generated by Penning et al. [23] as mem-
bers of a large group of molecules that were screened for
selective COX-2-inhibitory activity, an effort that ulti-
mately led to the discovery of CXB. Several years later, this
number of compounds was investigated by Chen's group
at Ohio State University for their ability to induce apopto-
sis in cultured prostate cancer cells. In these studies
[28,29], it was found that some of these compounds were
able to induce tumor cell death in vitro, but that this phar-
macologic activity did not correlate with the ability of the
individual analogs to inhibit COX-2. Thus, it was con-
cluded that apoptosis-inducing potency and COX-2-
inhibitory ability resided in different parts of the CXB
molecule and could be separated.
While much subsequent effort has been spent on fine-tun-
ing and improving the COX-2-independent acute cytotox-
icity of CXB analogs [27,30-33], essentially nothing is
Reduced cell growth and survival by CXB, UMC, and DMC in tumor cells with high or no COX-2 expression Figure 5
Reduced cell growth and survival by CXB, UMC, and DMC in tumor cells with high or no COX-2 expression. 
MIA-PaCa-2 (COX-2 negative) and Bx-PC-3 (high COX-2 expression) pancreatic carcinoma cells were treated with the indi-
cated concentrations of CXB, UMC, or DMC. After 48 hours, MTT assays were performed to indicate the overall viability in 
response drug treatment. The right panels show representative 96-well plates of treated cells. Deep purple indicates fully viable 
cell cultures, whereas yellow color reveals drug cytotoxicity (each condition was tested in duplicate). The single well labeled 
"Bg." represents background of medium alone without cells. The charts on the left present the quantitative readout of the opti-
cal density of the 96-well plates (average of two wells each). The whole experiment was independently repeated and yielded 
very similar outcomes.Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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known about the long-term effects of sub-toxic concentra-
tions of these compounds and whether or not the inhibi-
tion of COX-2 might emerge as a critical factor during
extended drug exposure. For this reason, we applied UMC
and DMC, which separately represent the two major char-
acterized functions of CXB, namely inhibition of COX-2
(preserved at increased potency in UMC) and induction of
apoptosis (preserved at increased potency in DMC).
Our results show that the IC50 for inhibition of COX-2 by
CXB or UMC in cell culture is below 1 µM, and 10 µM of
these drugs suffice to completely block COX-2 activity.
These results are in agreement with earlier studies report-
ing potent inhibition of PGE2 synthesis in cell culture by
submicromolar concentrations of CXB [34,35]. Intrigu-
ingly, at these low concentrations, neither CXB nor UMC
generated any detectable consequences for the cellular
phenotype. In particular, during short-term exposure,
there was no inhibition of cell proliferation, no increased
cytotoxicity, and no indication of ER stress (Figures 2, 3, 5
and 6); furthermore, during long-term exposure, these
concentrations were unable to prevent focus formation
(Figure 4) and did not reduce the compaction of cellular
monolayers (Figure 7). We therefore conclude that mere
inhibition of COX-2 does not impinge on tumor cell
growth and survival, and does not impede focus forma-
tion or high cell densities, even during very long incuba-
tion times.
In contrast to low concentrations (≤10 µM) of CXB and
UMC, further elevated concentrations of these com-
pounds began to generate observable changes in tumor
phenotype. However, it is noteworthy that UMC was sub-
stantially less effective than CXB in all these assays.
Because UMC is no less potent than CXB when it comes to
the inhibition of COX-2 and the reduction of cellular
PGE2 levels, it would be expected that any cellular pheno-
type that is triggered by or dependent on the inhibition of
COX-2 should become apparent at similar concentrations
of these two drugs. As this clearly is not the case, these
findings further support the conclusion that COX-2 has
no role in the antitumor effects we have measured in our
study.
DMC, which lacks substantial COX-2-inhibitory function,
displayed the most potent antitumor effects in our study.
The acute anti-proliferative and cytotoxic effects of this
compound have been investigated before and have
helped establish ER stress as potentially the most impor-
tant mechanism by which this drug – and CXB as well –
exert their cytotoxic effects [12,31,36,37]. Importantly, in
vivo studies verified that ER stress-mediated cytotoxicity
could also be achieved in experimental tumors of mice
that were fed CXB or DMC in their chow [12]. These latter
results helped refute earlier criticisms [38,39] that COX-2-
independent effects of CXB might be artifacts of the in
vitro culture system, a contention that was based on the
observation that the drug concentrations required to affect
most non-COX-2 targets in vitro were not achievable in
patients or animals. Although true that the induction of
ER stress in cell culture generally requires CXB or DMC
concentrations of ≥40 or ≥30 µM, respectively [12,17-19],
both drugs are able to trigger ER stress also in animal
tumors in vivo [12,19], where drug concentrations meas-
ured in the serum are below 10 µM [12,37]. Although a
solution to the conundrum of these differential drug con-
centration requirements has yet to be provided, these
types of experiments nonetheless strongly caution against
the tendency to minimize results that were obtained with
the use of moderately high micromolar concentrations of
celecoxib and DMC in vitro.
The vast majority of previous studies that investigated
antitumor mechanisms of CXB in vitro applied drug con-
centrations that proved cytotoxic, i.e., CXB concentrations
were increased to a level that effected proliferation-inhib-
itory and apoptosis-inducing outcomes within 24 to 96
hours. We reasoned that these acutely toxic effects of CXB,
which were mostly interpreted as being COX-2 independ-
ent, perhaps might obscure other, potentially COX-2
dependent, effects that otherwise might emerge only
when cells do not undergo immediate cell death. For this
reason, we applied CXB, UMC, and DMC at sub-toxic con-
centrations that did not trigger ER stress and subsequent
apoptosis. Under these much longer-term conditions, a
new feature of these drugs emerged, namely the ability to
restore contact inhibition and block focus formation of
tumor cells (Figures 4 and 7).
Increased expression of ER stress marker CHOP by CXB,  UMC, and DMC in tumor cells with high or no COX-2  expression Figure 6
Increased expression of ER stress marker CHOP by 
CXB, UMC, and DMC in tumor cells with high or no 
COX-2 expression. MIA-PaCa-2 (COX-2 negative) and 
Bx-PC-3 (high COX-2 expression) pancreatic carcinoma cells 
were treated with the indicated concentrations of CXB, 
UMC, or DMC for 18 hours and cell lysates were analyzed 
by Western blot with specific antibodies to CHOP (a pro-
apoptotic ER stress indicator protein) and actin (to verify 
equal loading in each lane).Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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Lower cell densities in the presence of CXB, DMC, and UMC Figure 7
Lower cell densities in the presence of CXB, DMC, and UMC. MIA-PaCa-2 (COX-2 negative) and Bx-PC-3 (high 
COX-2 expression) pancreatic carcinoma cells were continuously exposed to various concentrations of CXB, DMC, or UMC 
for up to 2 months in the same cell culture dishes (i.e., without splitting the cell monolayers). In A., cells were treated with or 
without 20 µM DMC and photomicrographs (400× magnification) were taken after 6 weeks. Note that in the presence of drug 
(lower panels) the individual cells are noticeably larger, and the overall monolayer consists of fewer cells per surface area. In B., 
cells were treated with increasing concentrations of CXB and the total number of cells per well (6-well plate) was determined 
after 4 weeks (shown is the average of two counts). In all instances, the phenotypic changes were similar in the case of CXB, 
UMC, or DMC (not shown for all treatment conditions), except that DMC was the most potent, and UMC the least potent, 
compound. These experiments were repeated with very similar outcomes.Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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The predisposition to form foci is a characteristic of many
cancer cells and indicates their acquired ability to disre-
gard the growth-inhibitory signals emanating from the
close contact with neighboring cells. This in vitro feature
is thought to reflect the in vivo ability of tumor cells to
escape social constraints within their tissue of origin and
might represent an important prerequisite for the initia-
tion of tumor growth [40]. In this context, it is tempting
to speculate that the ability of CXB to suppress focus for-
mation perhaps might represent a component of this
drug's recognized chemopreventive potential. However,
our results were obtained with the use of fully trans-
formed, malignant tumor cells in vitro, which represents
a poor model to study chemoprevention; therefore, better
models will be needed to further investigate our conjec-
ture. Similarly, with regards to therapeutic applications
for advanced cancers, CXB's ability to restore contact inhi-
bition conceivably could contribute to the reduced
growth of established tumors that has been reported in
many animal tumor models treated with this drug
(selected examples: [2,37,39,41]).
Conclusion
Our study shows that COX-2 inhibition by CXB has no
detectable consequences for various molecular and cellu-
lar markers of tumor growth in several glioblastoma and
pancreatic carcinoma cell lines with variable levels of
COX-2 expression. Inhibition of COX-2 per se is neither
required nor sufficient to implement the acutely growth-
inhibitory and cytotoxic effects of celecoxib, nor does it
impinge on the focus-forming ability of tumor cells dur-
ing chronic exposure at sub-toxic concentrations. Consist-
ent with several earlier reports [11,12,17-19], the
observed short-term antitumor effect of CXB closely corre-
lates with this drug's ability to trigger ER stress, and this
mechanism provides a reasonable explanation for the
drug's acutely growth-inhibitory effects. However, CXB's
potency to restore contact inhibition of tumor cells takes
place at drug concentrations that neither trigger substan-
tial ER stress nor cause cytotoxicity, and also cannot be
explained by the inhibition of COX-2. It therefore appears
that additional, as yet uncharacterized, molecular mecha-
nisms of this drug are at work during long-term, chronic
treatment of tumor cells. Considering that the envisioned
application of CXB for chemopreventive or therapeutic
anticancer purposes will require long-term drug exposure
of patients, it will be important to determine the molecu-
lar mechanisms that underlie this newly recognized abil-
ity of CXB to suppress focus formation during the chronic
treatment of tumor cells.
Materials and methods
Materials
CXB was obtained as Celebrex® capsules from the phar-
macy, or was synthesized in our laboratory according to
previously published procedures [23]. DMC was synthe-
sized in our laboratory according to previously published
procedures [31]. UMC as well was synthesized in our lab-
oratory according to previously published procedures
[23]. All compounds were dissolved in DMSO at 100 mM
(stock solution) and added to the cell culture medium in
a manner that kept the final concentration of solvent
below 0.1%.
Cell lines and culture conditions
The following human tumor cell lines were used: U251,
LN229, and T98G glioblastoma (kindly provided by Dr.
Frank B. Furnari, Ludwig Institute of Cancer Research, La
Jolla, CA) and MIA PaCa-2 and BxPC-3 pancreatic carci-
noma (kindly provided by Dr. Guido Eibl, UCLA, Los
Angeles, CA). All cells were propagated in DMEM (GIBCO
BRL, Grand Island, NY) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 0.1 mg/ml strep-
tomycin in a humidified incubator at 37°C and a 5% CO2
atmosphere.
MTT assays
MTT assays were performed in 96-well plates as described
in detail elsewhere [36]. All assays were repeated several
times at variable cell densities. The number of cells per
well ranged from 3.0 × 103 to 8.0 × 103.
Immunoblots
Total cell lysates were prepared and analyzed by Western
blot analysis with two different procedures. One was
based on conventional enzyme-linked chemolumines-
cence with HRP-conjugated secondary antibodies as
described earlier [31], the other used the Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, NE) and
fluorescence-conjugated secondary antibodies, according
to protocols supplied by the manufacturer. In both cases,
the primary antibodies were from Cell Signaling Technol-
ogies (Beverly, MA) or from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA) and were used according to the
manufacturers' recommendations. All immunoblots were
repeated at least once with new lysates from a duplicate
experiment to confirm the results.
Focus formation assays
Cells were seeded into 6-well plates at low density
(approximately 20% confluence). One day later, increas-
ing concentrations of celecoxib, DMC, or UMC were
added. After 4–5 days, untreated control cells had covered
the entire surface area of the well and began to form a
monolayer that became more compact over time. From
this time on, the growth medium and drugs were replaced
every two days. After approximately 10 days, focus forma-
tion became noticeable and was quantitated by counting
the number of foci per microscopic field every ten days. In
addition, digital images were captured with a SPOT cam-Molecular Cancer 2008, 7:38 http://www.molecular-cancer.com/content/7/1/38
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era model 1.4.0 operated with Spot Advanced Software
version 4.0.8 (Diagnostic Instruments, Sterling Heights,
MI) and saved in 12-bit grayscale format with 1600 x 1200
active pixels.
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